Oral Application
Non-soluble active molecules often exhibit low bioavailability, leading to poor effectiveness. To counter this issue, excessive doses are frequently required, which can result in first-pass metabolism effects, toxicity, and safety concerns.
LDS addresses these challenges by embedding poorly soluble and bioavailable active molecules at the interface of liquid nano-domains. These unique structures: (1) bypass the stomach while protecting the active molecule; (2) facilitate absorption in the upper layers of the gastrointestinal tract (GI); and (3) enable fast and efficient transport across membranes
Our specially designed structures allow the rapid transport of high loads of APIs with increased efficiency and safety.
Pre-clinical results demonstrate superiority
Partnership
In 2015, LDS entered into a partnership and license agreement with Ananda Scientifics, a US-based company, for oral delivery of cannabinoids. Ananda Scientifics has signed a long-term R&D agreement with LDS for future generations of oral cannabinoid-based products made in the form of soft-gels, instant powders, and dilutable liquids alone, or CBD together with other nutraceuticals such as curcumin, DHA, and more.
The technology is protected by patents issued in several countries and the nutraceutical products are currently sold in several markets around the globe under different brand names which yield royalties to LDS.
A first-in-human clinical trial (Phase 1A) for oral uptake of CBD was completed in 2020 with great success, demonstrating very fast CBD absorption (Tmax) and very high content of the CBD active ingredient into the bloodstream.
A Phase 2a is planned to start in Q4 of 2020. The studies are planned to demonstrate cannabinoids as opiate replacements and as a drug for two additional indications.
LDS is bringing continuous and progressive novelty and innovation into the cannabinoid markets.
